Last updated on July 2019

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

Brief description of study

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.

Detailed Study Description

This is a proof of concept study to evaluate the efficacy, safety and tolerability of abatacept in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

Clinical Study Identifier: NCT03215927

Find a site near you

Start Over